TY - JOUR
T1 - Reduction of HBV and HDV infection in two indigenous peoples of Peruvian Amazon after the vaccination against hepatitis B
AU - Cabezas, César
AU - Trujillo, Omar
AU - Balbuena, Johanna
AU - Terrazas, Manuel
AU - Manrique-de Lara, Carlos
AU - Marín, Luis
AU - Ramírez-Soto, Max Carlos
PY - 2020/1/1
Y1 - 2020/1/1
N2 - © 2020, Instituto Nacional de Salud Publica. Objective. To determine the outcome of the vaccination against hepatitis, we determined the prevalence of hepatitis B virus (HBV) and hepatitis D virus (HDV) infections, eight years after introduction of the vaccination. Materials and methods. A cross-sectional study was performed in 2 944 participants of 67 Kandozi and Chapra indigenous peoples in April 2010. Serological screening for hepatitis B surface antigen (HBsAg), antibody anti-HBc IgM and IgG, antibody anti-HBs and anti-HDV were determined by ELISA tests. Results. The prevalence rates of HBsAg, anti-HBc total, anti-HBs ≥10 mlUI/ml and anti-HDV were 2.3, 39.13, 50.95 and 2.11%, respectively. The prevalence rate of HBsAg in children <11 years was 0%. Among carriers of HBsAg, the prevalence rates of HDV and acute HBV infections were 2.11% (all were >14 years) and 11.94%, respectively. HBsAg and anti-HBc total were associated with individuals ≥10 years (p<0.001). Conclusions. These findings show the elimination of HBV carriers in children <11 years, eight years following introduction of the vaccination against HBV.
AB - © 2020, Instituto Nacional de Salud Publica. Objective. To determine the outcome of the vaccination against hepatitis, we determined the prevalence of hepatitis B virus (HBV) and hepatitis D virus (HDV) infections, eight years after introduction of the vaccination. Materials and methods. A cross-sectional study was performed in 2 944 participants of 67 Kandozi and Chapra indigenous peoples in April 2010. Serological screening for hepatitis B surface antigen (HBsAg), antibody anti-HBc IgM and IgG, antibody anti-HBs and anti-HDV were determined by ELISA tests. Results. The prevalence rates of HBsAg, anti-HBc total, anti-HBs ≥10 mlUI/ml and anti-HDV were 2.3, 39.13, 50.95 and 2.11%, respectively. The prevalence rate of HBsAg in children <11 years was 0%. Among carriers of HBsAg, the prevalence rates of HDV and acute HBV infections were 2.11% (all were >14 years) and 11.94%, respectively. HBsAg and anti-HBc total were associated with individuals ≥10 years (p<0.001). Conclusions. These findings show the elimination of HBV carriers in children <11 years, eight years following introduction of the vaccination against HBV.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85086356459&origin=inward
UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85086356459&origin=inward
U2 - 10.21149/11128
DO - 10.21149/11128
M3 - Article
SN - 0036-3634
SP - 237
EP - 245
JO - Salud Publica de Mexico
JF - Salud Publica de Mexico
ER -
